# US 2024/0173346 A1 · Line-1 inhibitors to treat cns and systemic diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0173346 A1
- Document ID: US20240173346A1
- Status: Published application
- Kind: A1
- Application number: 18/550,498
- Filed: 2022-03-15
- Published: 2024-05-30
- Earliest claimed: 2021-03-15
- Applicants: Transposon Therapeutics, Inc.
- Inventors: Eckard WEBER; Michael G. CORDINGLEY
- Web page: https://patentgrep.com/patent/US20240173346A1

## CPC

- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61P 31/18: for HIV
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides methods of treating or preventing a CNS or systemic disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a LINE-1 inhibitor, or a pharmaceutical composition thereof.

## Claims

### Claim 1

A method of treating or preventing a disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a LINE-1 inhibitor, or a pharmaceutical composition thereof, wherein the disease is ataxia-telangiectasia, age-related macular degeneration, systemic lupus erythematosus, IFN-associated autoimmune disease, Fanconi Anemia, idiopathic pulmonary fibrosis, or cardiovascular disease, and the LINE-1 inhibitor is censavudine,

### Claim 2 (depends on 1)

The method of claim 1, wherein the disease is ataxia-telangiectasia.

### Claim 3 (depends on 1)

The method of claim 1, wherein the disease is age-related macular degeneration.

### Claim 4 (depends on 1)

The method of claim 1, wherein the disease is systemic lupus erythematosus.

### Claim 5 (depends on 1)

The method of claim 1, wherein the disease is IFN-associated autoimmune disease.

### Claim 6 (depends on 5)

The method of claim 5, wherein the disease is psoriasis.

### Claim 7 (depends on 1)

The method of claim 1, wherein the disease is Fanconi Anemia.

### Claim 8 (depends on 1)

The method of claim 1, wherein the disease is idiopathic pulmonary fibrosis.

### Claim 9 (depends on 1)

The method of claim 1, wherein the disease is cardiovascular disease.

### Claim at position 10

10-12. (canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein the LINE-1 inhibitor is censavudine.

### Claim at position 12

14-16. (canceled)

### Claim 17 (depends on 1)

The method of claim 1 for treating the disease.

### Claim 18 (depends on 1)

The method of claim 1 for preventing the disease.

### Claim 19 (depends on 1)

The method of claim 1, further comprising administering one or more optional therapeutic agents to the subject.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The method of claim 1, wherein the subject is (a) not infected with the HIV virus, (b) is not suspected of being infected with the HIV virus, and/or (c) is not being treated to prevent infection with the HIV virus.

### Claim 22

A kit comprising a LINE-1 inhibitor, or a pharmaceutical composition thereof, and instructions of administering the LINE-1 inhibitor, or pharmaceutical composition thereof, to a subject having a disease, wherein the disease is ataxia-telangiectasia, age-related macular degeneration, systemic lupus erythematosus, IFN-associated autoimmune disease, Fanconi Anemia, idiopathic pulmonary fibrosis, or cardiovascular disease, and the LINE-1 inhibitor is censavudine,

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25 (depends on 22)

The kit of claim 22, wherein the LINE-1 inhibitor is censavudine.

### Claim at position 22

26-28. (canceled)

### Claim 29 (depends on 22)

The kit of claim 22 further comprising one or more optional therapeutic agents.

### Claim 30 (depends on 22)

The kit of claim 22, wherein the subject is (a) not infected with the HIV virus, (b) is not suspected of being infected with the HIV virus, and/or (c) is not being treated to prevent infection with the HIV virus.

### Claim 31 (depends on 1)

The method of claim 1, wherein the LINE-1 inhibitor is:

### Claim 32 (depends on 22)

The method of claim 22, wherein the LINE-1 inhibitor is:
